AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.

(Reuters) -AbbVie has obtained the option to license a new blood cancer drug candidate from Simcere Pharmaceutical's unit for ...

Learn more about Christopher Missling, PhD, on LinkedIn and explore the innovative work of Anavex Life Sciences at their website. In the relentless pursuit of solutions for neurodegenerative diseases ...

The vaccine candidate is under development for the treatment of HIV-1 infections. It comprises of HIVACAT T-cell immunogen (HTI) which is a chemically synthesized chimeric protein-encoding viral ...